0002023557-24-000001.txt : 20240528 0002023557-24-000001.hdr.sgml : 20240528 20240528162517 ACCESSION NUMBER: 0002023557-24-000001 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20240528 DATE AS OF CHANGE: 20240528 EFFECTIVENESS DATE: 20240528 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Absco Therapeutics, Inc. CENTRAL INDEX KEY: 0002023557 ORGANIZATION NAME: IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-514428 FILM NUMBER: 24992238 BUSINESS ADDRESS: STREET 1: 65 GLEN RD. APT. H2 CITY: BROOKLINE STATE: MA ZIP: 02445 BUSINESS PHONE: 314-917-7620 MAIL ADDRESS: STREET 1: 65 GLEN RD. APT. H2 CITY: BROOKLINE STATE: MA ZIP: 02445 D 1 primary_doc.xml X0708 D LIVE 0002023557 Absco Therapeutics, Inc. 65 GLEN RD. APT. H2 BROOKLINE MA MASSACHUSETTS 02445 314-917-7620 DELAWARE None None Corporation true 2024 Stephen Linderman 65 GLEN RD. APT. H2 BROOKLINE MA MASSACHUSETTS 02445 Executive Officer Director Avik Som 65 GLEN RD. APT. H2 BROOKLINE MA MASSACHUSETTS 02445 Director Carlo Giovanni Traverso 65 GLEN RD. APT. H2 BROOKLINE MA MASSACHUSETTS 02445 Director Biotechnology Decline to Disclose 06b false 2024-05-10 false true true false 0 2000000 2000000 0 false 1 0 0 0 false Absco Therapeutics, Inc. /s/ Stephen Linderman Stephen Linderman Chief Executive Officer 2024-05-28